Initial data from the arc-20 study of casdatifan plus cabozantinib showed nearly half of patients with metastatic kidney cancer had a confirmed response

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by dr. toni k. choueiri, dana-farber cancer institute, at the 2025 american society of clinical oncology (asco) annual meeting. “i was very encouraged to see that nearly half of patients had a.
RCUS Ratings Summary
RCUS Quant Ranking